Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival
Pooled Analysis of 12 Seperate Yervoy Studies Shows Survival-Curve Plateau at 3 Years
Perjeta Neoadjuvant Therapy Granted Accelerated Approval In HER2 Breast Cancer
ASCO and CAP Issue Guideline To Improve HER2 Testing
Phase III Ramucirumab Trial Fails Primary Endpoint of PFS
Kadcyla Extends Median PFS In Open-Label Phase III Trial
Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease
Colon Polyps in Elderly Patients Are More Likely to Be Found Only with Colonoscopy
Phase III Vaccine Trial Fails To Improve Overall Survival
Central Line Safety Intervention Lowers Patient Infection Rate
Phase II Study Shows Positive Results in Reducing Dry Mouth
NCI CTEP Approved Trials For the Month of October
Trending Stories
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- What are The CheckPoints movin’ and groovin’ to this summer?
Join the journal club with the best bops: We asked SITC’s 13-piece band of medical musicians for the top papers and songs of the summer - Senate passes stopgap bill that would ban OMB from finalizing rule that would politicize science
- The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion
